# A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

> **NCT03357627** · PHASE1 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 43 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Large B-cell, Diffuse
- Lymphoma, Follicular

## Interventions

- **DRUG:** TAK-659
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03357627
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-16
- **Primary completion:** 2021-08-03
- **Final completion:** 2021-08-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357627, "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03357627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*